Get the Stockscreener App
2.20
5.26%
0.11
After Hours:
2.03
-0.17
-7.73%
Gain Therapeutics Inc stock is traded at $2.20, with a volume of 265.78K.
It is up +5.26% in the last 24 hours and up +0.92% over the past month.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.
See More
Previous Close:
$2.09
Open:
$2.1
24h Volume:
265.78K
Relative Volume:
1.09
Market Cap:
$57.82M
Revenue:
$210.70K
Net Income/Loss:
$-21.37M
P/E Ratio:
-2.00
EPS:
-1.1
Net Cash Flow:
$-21.10M
1W Performance:
-1.35%
1M Performance:
+0.92%
6M Performance:
+98.20%
1Y Performance:
-43.15%
1-Day Range:
$2.045
$2.26
1-Week Range:
$1.96
$2.30
52-Week Range:
$0.89
$5.33
Gain Therapeutics Inc Stock (GANX) Company Profile
Name
Gain Therapeutics Inc
Sector
Industry
Phone
(301) 500-1556
Address
4800 HAMPDEN LANE, BETHESDA
Compare GANX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
2.20 | 57.82M | 210.70K | -21.37M | -21.10M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Aug-14-24 | Resumed | Oppenheimer | Outperform |
| Apr-12-21 | Initiated | BTIG Research | Buy |
| Apr-12-21 | Initiated | Oppenheimer | Outperform |
Gain Therapeutics Inc Stock (GANX) Latest News
UiPath Inc (PATH) Forecast: Revisiting The Past To Gain Insights For The Future - Stocks Register
Medicare Advantage Members Gain Access to Innovative Digital Therapeutics Through New Partnership - PR Newswire
This Weight-Loss Drug Stock Could Gain 200%, Challenge Novo Nordisk, Eli Lilly. - Barron's
Investors in Seres Therapeutics (NASDAQ:MCRB) from three years ago are still down 88%, even after 17% gain this past week - Simply Wall St
Vir, Sana gain new modality POC: BioCentury’s Clinical Report - BioCentury
Improved Revenues Required Before Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock's 30% Jump Looks Justified - Simply Wall St
Will CRL Stock Gain From Integration of Akron Bio's CSS Product Line? - Yahoo Finance
Perrigo cut to Hold at Argus on topline risks - MSN
Regions Financial Q4 2024 Earnings Preview - MSN
All You Need to Know About Gain Therapeutics (GANX) Rating Upgrade to Strong Buy - MSN
Gain Therapeutics regains compliance with Nasdaq listing By Investing.com - Investing.com South Africa
Gain Therapeutics regains compliance with Nasdaq listing - Investing.com India
Parkinson's Disease Clinical and Non-Clinical Studies, Key - openPR
Stock market today: Eterna Therapeutics gain over 136.63% while Phio Pharmaceuticals plunged by 40.25% in early trading - Business Upturn
Stock market news: Eterna Therapeutics posted gain of 100.87% while Phio Pharmaceuticals saw loss of 50.44% during mid day trading - Business Upturn
Geode Capital Management LLC Has $484,000 Stock Holdings in Gain Therapeutics, Inc. (NASDAQ:GANX) - Defense World
Pre-market Movers: AVGR, TIVC, ATNF, SLGL... - RTTNews
Coinbase Global Inc (COIN) Forecast: Revisiting The Past To Gain Insights For The Future - Stocks Register
Best Momentum Stocks to Buy for January 9th - Yahoo Finance
Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287 - The Manila Times
Gain Therapeutics Forms Elite Advisory Board to Accelerate Parkinson's Drug Development - StockTitan
Gain Therapeutics (GANX) Shares Rise In After-Hour Trading - Stocks Telegraph
Gain Therapeutics Appoints New CEO Amidst Clinical Progress - TipRanks
Gain Therapeutics Appoints Gene Mack as Chief Executive Officer - Marketscreener.com
Gain Therapeutics appoints new CEO and finance SVP - Investing.com
Gain Therapeutics Appoints Gene Mack as CEO - citybiz
Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director - The Manila Times
Gain Therapeutics Names Gene Mack as CEO, Advancing Parkinson's Disease Drug Development - StockTitan
Viking Therapeutics, Inc. (VKTX) Stock Sinks As Market Gains: What You Should Know - MSN
Drug Innovator Launches Pivotal Cancer Trial Breakthrough - Streetwise Reports
Miami Biopharma Sells Part of Business & Begins New Clinical Trial - Streetwise Reports
Tarsus PharmaceuticalEye Care Therapeutics - TradingView
Gold just saw its biggest yearly gain since 2010 — here's why Wall Street says prices will go even higher - Yahoo Finance
Analyst Sees Major Growth for Biopharma With Weight-Loss Drug - Streetwise Reports
Gain Therapeutics: Parkinson's Drug Candidate GT-02287 Keeps Racking Up Good Results - Seeking Alpha
Analyst Initiates Coverage of Co. With 'Once-in-a-Generation' Drug - Streetwise Reports
Parkinson's Treatment Advancements: Clinical Trials Begin for Potential New Therapy - Streetwise Reports
Viking Therapeutics, Inc. (VKTX) Gains As Market Dips: What You Should Know - MSN
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Large Increase in Short Interest - MarketBeat
Protara Therapeutics, Inc. (NASDAQ:TARA) Sees Large Increase in Short Interest - MarketBeat
Maryland Biotech Gains Regulatory Approval - Streetwise Reports
Investing in Travere Therapeutics (NASDAQ:TVTX) a year ago would have delivered you a 82% gain - Yahoo Finance
Gain Therapeutics’ GT-02287 study to deliver positive findings, says Roth MKM - Yahoo Finance
Gain Therapeutics (NASDAQ:GANX) Receives Buy Rating from Roth Mkm - Defense World
Gain Therapeutics (NASDAQ:GANX) Initiates Phase 1b Clinical Trial for GT-02287 in Australia - Defense World
S&P 500, Nasdaq gain in choppy trading as most megacaps move higher - MSN
Why RAPT Therapeutics Stock Gained Over 100% On Monday? - Benzinga
Sage Therapeutics (SAGE) Surges 12.2%: Is This an Indication of Further Gains? - MSN
Gain Therapeutics Advances GT-02287 into Phase 1b Trial - TipRanks
Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson's Disease - The Manila Times
Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with - The Bakersfield Californian
Gain Therapeutics Inc Stock (GANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):